MUFG Securities EMEA plc Grows Stock Holdings in IQVIA Holdings Inc. $IQV

MUFG Securities EMEA plc boosted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 114.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,977 shares of the medical research company’s stock after buying an additional 3,723 shares during the quarter. MUFG Securities EMEA plc’s holdings in IQVIA were worth $1,573,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Ameliora Wealth Management Ltd. bought a new stake in IQVIA during the fourth quarter valued at approximately $25,000. International Assets Investment Management LLC bought a new stake in IQVIA during the fourth quarter valued at approximately $27,000. Activest Wealth Management grew its position in IQVIA by 590.0% during the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock valued at $31,000 after buying an additional 118 shares during the period. Physician Wealth Advisors Inc. grew its position in IQVIA by 1,340.0% during the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after buying an additional 134 shares during the period. Finally, Westside Investment Management Inc. grew its position in IQVIA by 219.6% during the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after buying an additional 101 shares during the period. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Performance

IQV opened at $180.52 on Wednesday. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. The company has a 50 day simple moving average of $170.76 and a two-hundred day simple moving average of $195.83. IQVIA Holdings Inc. has a 1-year low of $136.41 and a 1-year high of $247.04. The firm has a market cap of $30.13 billion, a P/E ratio of 22.37, a PEG ratio of 1.79 and a beta of 1.21.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The firm had revenue of $4.15 billion during the quarter, compared to analyst estimates of $4.10 billion. During the same quarter in the prior year, the business earned $2.70 earnings per share. IQVIA’s revenue for the quarter was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA declared that its Board of Directors has authorized a share buyback program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to buy up to 6.8% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s board believes its shares are undervalued.

Analyst Ratings Changes

Several brokerages recently issued reports on IQV. Jefferies Financial Group cut their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Barclays upgraded shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 target price for the company in a research report on Friday, March 6th. Truist Financial cut their target price on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research report on Thursday, February 19th. Royal Bank Of Canada assumed coverage on shares of IQVIA in a research report on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 price target for the company. Finally, JPMorgan Chase & Co. dropped their price target on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a research report on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $225.69.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.